Dr. Monk on Immunotherapy for Gynecologic Cancer

Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses immunotherapy for patients with gynecologic cancer.

Immunotherapy is important in all types of gynecologic cancers, explains Monk. In cervical cancer, there is a randomized phase III trial about to begin regarding a checkpoint inhibitor.

Pembrolizumab (Keytruda) is an important regimen in microsatellite instability-high recurrent endometrial cancer for the second-line setting. This could potentially be the first checkpoint inhibitor approved for a gynecologic cancer, states Monk.